Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 27, 2025
Patient-reported outcomes in LITESPARK-005: a timely step toward patient-centered metrics in advanced renal cell carcinoma.
Journal: Chinese clinical oncology
Published: August 15, 2025
Immune-based Therapies for Penile Cancer.
Journal: The Urologic clinics of North America
Published: June 26, 2024
Overview of Systemic Therapies in Penile Cancer.
Journal: The Urologic clinics of North America
Published: June 26, 2024
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 21, 2024
Insights into the management of penile squamous cell carcinoma: from conventional approaches to emerging novel therapies.
Journal: Expert opinion on pharmacotherapy
Published: March 29, 2024
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Journal: Oncoimmunology
Published: December 21, 2023
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis.
Journal: EClinicalMedicine
Published: November 10, 2023
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management.
Journal: Targeted oncology
Published: November 22, 2022
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.
Journal: Clinical genitourinary cancer
Published: October 17, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Journal: Journal for immunotherapy of cancer
Published: January 26, 2021
Last Updated: 09/26/2026